Marked increases in case rates of drug-resistant tuberculosis and nontuberculous
mycobacterial infections have brought renewed urgency to the development of new …

Chemotherapy for mycobacterial disease began in the late 1940s with the introduction of
streptomycin (SM). Rifampin (RIF), the most recent major new therapeutic innovation, was …

This book is comprised of reviews on the chemotherapy of mycobacterial infections, as well
as descriptions of established methods and new techniques for drug susceptibility testing …

Historically, mycobacterial infections have been associated with signifi cant morbidity and
mortality worldwide. In particular, Mycobacterium tuberculosis is a highly successful human …

Sterilizing drugs kill Mycobacterium tuberculosis that persists during chemotherapy.
Predictive models should mimic the conditions causing persistence in the lesions of cavitary …

The biological activity of a drug determined in vitro (eg, the minimal inhibitory concentration)
is a parameter decisive in determining the effect of antituberculotics on mycobacteria in a …

Background: The second-line drugs recommended to treat drug-resistant TB are toxic,
expensive and difficult to procure. Given increasing resistance, the need for additional anti …

Novel treatment strategies for tuberculosis are urgently needed. Many different preclinical
models assessing anti-tuberculosis drug activity are available, but it is yet unclear which …

Although Mycobacterium tuberculosis is eradicated rapidly during therapy in some patients
with pulmonary tuberculosis, it can persist for many months in others. This study examined …

Diseases caused by nontuberculous mycobacteria are emerging in many settings. With an
increased number of patients needing treatment, the role of drug susceptibility testing is …